Asbestos, Mesothelioma, and Talc Litigation – Fast Evaluation (2026)

Written by Michael Stanisci (MassTortMichael)

What the trust spreadsheet tells us, plus where mesothelioma and talcum powder claims fit in.

Asbestos in 2026: The Checks Are Shrinking. The Lawsuits Are Not. Why?

1) Snapshot

Asbestos is the oldest mass tort in America, and in 2026 it is not slowing down. New filings hit 4,244 in 2025, the highest level since 2017, and mesothelioma cases crossed 2,000 for the first time in six years. At the same time, the bankruptcy trust system that pays a big chunk of these claims is getting tighter. Our trust spreadsheet (dated 5/23/2026) shows most trusts paying a smaller slice of their scheduled values than they did in 2018. The growth engine right now is talc. Four in ten mesothelioma claims filed in 2025 included a talc allegation, and Johnson & Johnson is back in the tort system after its third bankruptcy attempt was thrown out. [Cite 1, 2, 3, 4]

2) What the Data Shows

I've collaborated to track 100+ asbestos bankruptcy trusts. Scheduled settlement values by disease level (Level VIII is the most severe category, which is mesothelioma at most trusts) and the payment percentage each trust paid in 2018 versus 2026. Here is what the numbers say when you run them.

The scheduled values look big. The checks are not.

• 76 trusts publish a Level VIII (mesothelioma) scheduled value. The median is about $113,500. The mean is about $129,000.

• But a claimant never gets the scheduled value. They get the scheduled value times the payment percentage. That percentage exists so the trust does not run out of money before future victims file.

Payment percentages are falling at most trusts.

• 48 trusts in the sheet show a payment percentage for both 2018 and 2026.

• 26 of those trusts cut their percentage. 16 raised it. 6 held flat.

• The median payment percentage fell from about 18.4% in 2018 to about 11.6% in 2026.

• The median effective mesothelioma payout per trust fell from roughly $18,500 to roughly $11,000.

The big-name cuts are dramatic.

• United States Gypsum (USG): 45% down to 11%.

• Babcock & Wilcox: 34% down to 4.7%.

• Kaiser Aluminum: 39.5% down to 10.6%.

• Owens Corning: 11.1% down to 4.7%.

• Armstrong World Industries: 20% down to 10.8%.

• These cuts match what trust trackers reported through 2025 and 2026, including the Motors Liquidation (GM) trust dropping from 12.2% to 10.3% in March 2026. [Cite 5]

A smaller group of trusts is paying more.

• Christy Refractories: 11% up to 55%.

• Western Asbestos/MacArthur (MN): 31.5% up to 51.1%. That makes it the single richest line in the sheet, with an effective mesothelioma payout around $161,600.

• ASARCO: 22% up to 35%.

• NARCO is listed at 100%, and the newer Owens-Illinois Paddock trust (2022) pays 50% on a $120,000 schedule, about $60,000 effective.

The system is aging out at the edges.

• Five trusts in the sheet are closed (A&I Corp, EJ Bartells, Rapid American, Oakfabco, UNARCO).

• At least seven more, including Garlock, do not publish values at all.

So what does this all mean?  A mesothelioma claimant does not get paid by one trust. They stack claims across every trust where they can prove exposure. If a single claimant somehow qualified at all 48 trusts with full data, the combined effective payout would be about $1 million. Real claimants qualify at far fewer trusts, often 5 to 15. So the trust side of a strong mesothelioma case typically produces a combined recovery in the low to mid six figures, and the trend line on that number is down. Industry trackers estimate roughly $30 billion still sits in 60-plus active trusts. [Cite 5, 6, 7]

Here's the story: trust money is real but shrinking per claim. The tort system, and especially talc defendants, is where case values are growing.

3) Plaintiff Numerosity (PPN)

• Total asbestos filings: 4,244 in 2025, up almost 6% from 2024, the highest since 2017. Filings have risen three straight years. [Cite 1, 8]

• Mesothelioma: 2,035 filings in 2025, about 48% of the total. Lung cancer was about 40%. Serious cancer claims now make up nearly 9 in 10 asbestos filings. [Cite 1]

• Important caution: KCIC notes that actual mesothelioma and lung cancer diagnoses are falling per SEER and CDC data. Filings are rising anyway. That means a higher share of diagnosed patients are suing, not more disease. The pool is finite. Roughly 3,000 Americans are diagnosed with mesothelioma per year, so the practical PPN ceiling for new mesothelioma claims is a few thousand per year. [Cite 8]

• Talc changes the math. In 2021 about 17% of mesothelioma claims included a talc allegation. In 2025 it was about 40%, and talc-only filings grew 47% in one year. Talc also opens the door to claimants with no industrial work history, including many women. [Cite 4]

• Talc ovarian cancer is its own, much larger universe. Around 67,000 to 70,000 cases sit in the J&J federal MDL, with more in state courts. [Cite 9, 10]

• Mensing does not apply here. These are not generic drug claims. SOL is claim by claim and many states apply the discovery rule generously to latent disease.

4) Defendant Viability

• The original asbestos manufacturers are mostly gone. Their liabilities live in the trusts on the spreadsheet. The remaining tort-system defendants are mostly solvent peripheral companies: equipment makers, premises owners, auto parts, and talc-related companies. The average asbestos complaint now names about 75 defendants. [Cite 2]

• Johnson & Johnson is the giant. It has a market cap in the hundreds of billions and was found solvent across three bankruptcy attempts. It can pay. The fight is over how much and when. [Cite 11]

• Two-step bankruptcy risk is alive. Bestwall (Georgia-Pacific, owned by Koch) has been in Chapter 11 since 2017 with roughly 56,000 to 62,000 claimants unpaid. The Fourth Circuit upheld the bankruptcy in August 2025. Claimants asked the Supreme Court to take the case in February 2026, and a bipartisan group of senators filed a brief against the two-step in March 2026. Reports indicate Georgia-Pacific may be preparing a fresh filing. [Cite 12, 13]

• Whittaker, Clark & Daniels, a defunct talc supplier tied to Berkshire Hathaway, has so far survived challenges to its New Jersey bankruptcy at the Third Circuit, with rulings in 2025 and April 2026. [Cite 14, 15]

• Lesson: in the Fifth Circuit (J&J) and Third Circuit (LTL), the two-step has failed. In the Fourth Circuit (Bestwall, Aldrich Pump) it has survived so far. Where a defendant can file matters as much as what they did.

5) Financial Viability

• Trusts: about $30 billion remains across active trusts, but payment percentages are managed down to stretch that money over decades of future claims. Expect more cuts than raises. [Cite 5, 6]

• J&J: It proposed roughly $9 to $10 billion in its Red River plan, which would have paid ovarian claimants an estimated $75,000 to $150,000 each. The court rejected the plan, partly because a single verdict already exceeded what the plan offered some claimants. J&J says it has resolved about 95% of filed mesothelioma talc claims through settlements outside bankruptcy. [Cite 11, 16]

• Imerys (J&J's former talc supplier) remains in its own bankruptcy, with a possible payout timeline emerging in 2026. [Cite 17]

6) Scientific Viability

• Asbestos causes mesothelioma. This is settled science and has been for decades. Causation in a classic asbestos case is about proving exposure to a specific defendant's product, not about whether asbestos causes disease.

• Talc mesothelioma rests on evidence that certain talc deposits were contaminated with asbestos. Juries have repeatedly accepted this, including verdicts of $65.5 million in Minnesota and $1.5 billion in Baltimore in December 2025. J&J calls the science junk and appeals everything. [Cite 18, 19]

• Talc ovarian cancer is the more contested theory. In February 2026, court-appointed special master Freda Wolfson (the retired judge who ran the MDL for years) issued a 658-page recommendation allowing plaintiff expert testimony linking genital talc use to ovarian cancer, finding the epidemiology shows a statistically significant association. That is a major Daubert-style win for plaintiffs heading into bellwethers. [Cite 10]

7) Time to Resolution (PCD)

• Trust claims: fast. Expedited review claims can pay in months. This is the cash-flow advantage of asbestos work.

• Tort-system mesothelioma cases: many states give dying plaintiffs trial preference. Cases can resolve in 1 to 2 years.

• Talc ovarian (J&J): uncertain. The bankruptcy pause ended in 2025. Trials are running through 2026, with 10 or more expected in the first half alone, and the first MDL bellwether expected later in 2026. No global settlement exists as of early June 2026. A reasonable range is 2 to 5 more years, with bankruptcy maneuver risk as the wild card. [Cite 9, 20]

• Bestwall claimants have waited 8-plus years with zero paid. That is the cautionary tale for any docket trapped in a two-step. [Cite 13]

8) Venue

• This is not one MDL. Classic asbestos runs through state courts. Madison County and St. Clair County, Illinois remain the epicenters, and Illinois passed a law in August 2025 expanding its courts' reach over asbestos cases. [Cite 21]

• Talc ovarian: MDL 2738, District of New Jersey (In re Johnson & Johnson Talcum Powder). Roughly 67,670 cases pending at the end of 2025, with 441 added in November 2025 alone. Philadelphia, Los Angeles, and other state dockets are also active. [Cite 9, 22]

9) Bellwether and Trial Results

Since J&J returned to the tort system, plaintiffs are winning most trials:

• December 2025: Los Angeles jury awarded $40 million to two ovarian cancer plaintiffs in the first post-bankruptcy trial. [Cite 20]

• December 2025: Minnesota jury awarded $65.5 million in a mesothelioma case. [Cite 18]

• December 2025: Baltimore jury awarded over $1.5 billion in a peritoneal mesothelioma case, believed to be the largest single-plaintiff talc verdict ever. [Cite 19]

• February 2026: Philadelphia jury awarded $250,000 in an ovarian cancer death case. A win, but a small one, and a reminder that verdicts vary wildly by venue and facts. [Cite 22]

Remember the rule: verdict size does not equal settlement value. Big verdicts pressure J&J toward a global deal, but they do not set per-case settlement numbers.

10) State of Litigation

• Asbestos generally: filings rising, talc allegations spreading, defendant lists growing, Illinois consolidating its hotspot status. [Cite 1, 21]

• Trusts: more cuts than raises, several closures, the system slowly winding down per claim even as money keeps flowing in aggregate. (Spreadsheet analysis; Cite 5)

• J&J talc: Red River bankruptcy dismissed March 31, 2025 by Judge Christopher Lopez in the Southern District of Texas, citing voting irregularities, impermissible third-party releases after the Supreme Court's Purdue ruling, and lack of good faith. J&J chose to litigate rather than appeal. Trials and bellwether prep now dominate 2026. [Cite 11, 16]

• Two-step watch: Bestwall cert petition pending at the Supreme Court as of February 2026. The outcome could reshape every future mass tort bankruptcy. [Cite 12]

11) Business View

Note on values below: all case values are estimates. Individual results will vary widely based on disease, exposure proof, venue, age, and dozens of other factors.

Classic mesothelioma (occupational asbestos)

• Risk level (1-10): 2. The most mature, predictable mass tort in existence. The risk is competition and a finite patient pool, not legal viability.

• PACV range: combined recoveries (trusts plus tort settlements) commonly reach $1 million to $2 million-plus in well-worked cases, per industry settlement reporting. Trust-only recoveries are far lower and shrinking. [Cite 7]

• PPN signal: Low in volume, roughly 2,000 filings a year, but each case is extremely high value.

• TCPCA guidance: Mesothelioma is famously the most expensive keyword market in legal advertising. CPCA can run into the tens of thousands. The math still works because PACV is enormous and PCD is short, which keeps the NPV strong even at a high RR. Phase logic matters less here since this is a steady-state practice, not a single litigation with an inception phase.

• Suggested posture: Enter only with deep pockets or a strong referral relationship. Otherwise, refer cases out and protect your fee in the retainer.

Talc mesothelioma

• Risk level (1-10): 3. Juries accept the contamination evidence and J&J settles most of these. The residual risk is appellate reversals and supplier bankruptcies (Whittaker, Imerys).

• PACV range: estimated mid six figures to seven figures based on verdict patterns and J&J's reported 95% settlement rate on filed meso claims. These are estimates and individual results will vary. [Cite 16, 18]

• PPN signal: Medium and growing. 40% of new meso claims now include talc, and talc-only filings grew 47% in 2025. [Cite 4]

• TCPCA guidance: Screening must capture non-occupational exposure. The qualifying client may be a woman with decades of cosmetic powder use, not a pipefitter. That widens the ad audience and can lower CPCA versus classic meso advertising.

• Suggested posture: Enter now. This is the growth segment of asbestos litigation with a solvent primary defendant.

Talc ovarian cancer (J&J)

• Risk level (1-10): 5 to 6. Science cleared a major hurdle with the Wolfson recommendation, plaintiffs are winning trials, and bankruptcy failed three times. But there is no settlement structure, verdicts swing from $250,000 to $40 million, appellate risk is real, and a fourth bankruptcy maneuver or congressional change cannot be ruled out.

• PACV range: J&J's own rejected plan pointed at $75,000 to $150,000 per ovarian claimant. A negotiated tort-system deal after strong bellwethers could land higher. Treat anything above the plan range as upside, not a base case. These are estimates and individual results will vary. [Cite 16]

• PPN signal: High. Roughly 70,000 pending cases and the pipeline is still filling. [Cite 9, 22]

• TCPCA guidance: With a PACV midpoint near $100,000, a 40% fee, a 40% referral share, and a 3 to 4 year PCD at a moderate RR, an acceptable ACPCA sits well below what perfect-storm cases support. Keep CPCA disciplined. This is a volume play with compressed per-case fees, not a Yaz.

• Suggested posture: Watch leaning enter. Sign carefully screened cases at low CPCA. The first MDL bellwether later in 2026 is the milestone to re-evaluate everything.

Acronyms

• ACPCA: Average Cost Per Client Acquired. Your average acquisition cost across the life of your involvement in a case.

• AE: Adverse Event. The injury or illness linked to the product.

• BBW: Black Box Warning. The FDA's strongest drug warning. Not directly relevant to asbestos, but part of our standard framework.

• CDC: Centers for Disease Control and Prevention.

• CMO: Case Management Order. A judge's order controlling how a case proceeds.

• CPCA: Cost Per Client Acquired. What you spend to sign one client.

• FDA: U.S. Food and Drug Administration.

• JPML: Judicial Panel on Multidistrict Litigation. The panel that creates and assigns MDLs.

• KCIC: A Washington, D.C. consultancy that tracks roughly 90% of U.S. asbestos filings.

• MDL: Multidistrict Litigation. Federal cases with common facts consolidated before one judge for pretrial work.

• NPV: Net Present Value. What future money is worth today.

• PACV: Potential Average Case Value. The estimated average settlement value per case.

• PCD: Potential Case Duration. The estimated time until cases pay.

• PPN: Potential Plaintiff Numerosity. The estimated number of potential plaintiffs.

• PTO: Pre-Trial Order.

• RR: Required Rate of Return. The return you demand for the risk, expressed as an interest rate.

• SEER: Surveillance, Epidemiology, and End Results. The National Cancer Institute's cancer statistics program.

• SOL: Statute of Limitations. The deadline to file a claim.

• TCPCA: Target Cost Per Client Acquired. The most you can pay per client and still hit your required return.

• TDP: Trust Distribution Procedures. The published rules each asbestos trust uses to value and pay claims.

Open Items

• KCIC's full 2025 Year in Review report is behind a registration wall. Jurisdiction-level filing counts should be pulled directly when needed. [Cite 1, 3]

• The Supreme Court has not yet acted on the Bestwall cert petition as of this writing. That decision could change the two-step risk picture overnight.

• Several trusts in the spreadsheet list values as not published (Garlock, Kaiser Gypsum details, Anaconda/ARCO, others). Effective payouts there cannot be verified.

• Georgia-Pacific's reported new bankruptcy filing has not been confirmed in a court docket as of this writing. Treat it as a credible report, not a fact. [Cite 13]

Contact Michael

• If you are a potential claimant, I can help connect you with the right law firm.

• If you are an attorney, I can help end-to-end: improve operations, add the right tech, and grow with new claimant acquisition.

• Website: https://www.masstortmichael.com/

• Email: michael@masstortmichael.com

• Phone: 908-548-5378

Copyright

• Copyright © Nisci Consulting LLC & MassTortMichael. Please share this evaluation with attribution to help more firms make sound decisions.

Citations

1. Asbestos.com, Mesothelioma Lawsuit Filings Highest Since Prepandemic Levels (May 18, 2026) – https://www.asbestos.com/news/2026/05/18/mesothelioma-lawsuit-filings-highest-since-prepandemic-levels/

2. Sokolove Law, Asbestos & Mesothelioma Litigation History – https://www.sokolovelaw.com/mesothelioma/legal/mesothelioma-lawsuit/litigation-history/

3. KCIC, 2025 Asbestos Litigation Year in Review announcement (April 29, 2026) – https://www.kcic.com/trending/feed/its-here-download-kcic-s-2025-asbestos-litigation-report/

4. Sokolove Law, 4 in 10 Mesothelioma Lawsuits Involve Talc Exposure (May 2026) – https://www.sokolovelaw.com/blog/40-percent-of-mesothelioma-claims-involve-talc-exposure/

5. ELSM Law, Asbestos Trust Funds: Lists, Payouts & Bankrupt Defendants – https://www.elslaw.com/legal-rights/asbestos-trust-funds/

6. Sam & Dan Law, Asbestos Trust Funds: Payouts, List & How to File (2026) – https://www.samndan.com/mesothelioma/asbestos-trust-funds/

7. Asbestos.com, Mesothelioma Settlements & Verdicts: Average Payouts in 2026 – https://www.asbestos.com/mesothelioma-lawyer/settlements/

8. KCIC, Sharing a Preview of 2025 Asbestos Filings, Perrin Conference (March 2026) – https://www.kcic.com/trending/feed/sharing-a-preview-of-2025-asbestos-filings-at-perrin-s-2026-cutting-edge-issues-in-asbestos-litigation-conference/

9. Darrow.ai, Johnson & Johnson Talc Lawsuit: History & 2026 Updates – https://www.darrow.ai/resources/johnson-and-johnson-talc-lawsuit

10. Lawsuit Information Center, Talc Baby Powder Lawsuit Updates (June 2026) – https://www.lawsuit-information-center.com/2-billion-verdict-in-missouri-motivates-jj-to-settle-talcum-powder-lawsuits.html

11. Cadwalader, J&J's Red River Bankruptcy Strategy Sinks (April 2025) – https://www.cadwalader.com/resources/clients-friends-memos/johnson--johnsons-red-river-bankruptcy-strategy-sinks-on-third-party-release-issues-voting-irregularitieswith-possible-implications-for-future-mass-tort-bankruptcy-cases

12. Bloomberg Law, Georgia-Pacific Unit's Claimants Appeal Bankruptcy to High Court (Feb. 23, 2026, paywalled) – https://news.bloomberglaw.com/bankruptcy-law/georgia-pacific-units-claimants-appeal-bankruptcy-to-high-court

13. DuBose Law Firm, Georgia-Pacific Is Preparing a New Asbestos Bankruptcy (April 2026) – https://duboselawfirm.com/georgia-pacific-asbestos-bankruptcy-2026/

14. Bloomberg Law, Ex-Talc Supplier Bankruptcy Survives Despite Creditor Pleas (Sept. 2025, paywalled) – https://news.bloomberglaw.com/bankruptcy-law/ex-talc-supplier-to-stay-in-bankruptcy-despite-creditors-pleas

15. Law360, 3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11 (April 27, 2026, paywalled) – https://www.law360.com/bankruptcy/articles/2470269

16. Asbestos.com, Judge Rejects J&J's $10 Billion Talc Settlement (April 2025) – https://www.asbestos.com/news/2025/04/09/judge-rejects-jj-settlement/

17. Sokolove Law, Talcum Powder Settlement Amounts & Verdicts (June 2026) – https://www.sokolovelaw.com/product-liability/talcum-powder/settlements/

18. Drugwatch, Johnson & Johnson Talcum Powder Lawsuit (June 2026) – https://www.drugwatch.com/talcum-powder/lawsuits/

19. Minnesota Lawyer, J&J Verdicts Set Stage for Talc 2026 Litigants (Jan. 2026) – https://minnlawyer.com/2026/01/19/johnson-johnson-talc-cancer-verdicts/

20. Business Wire, Philadelphia Jury Returns $250,000 Verdict Against J&J (Feb. 2026) – https://www.businesswire.com/news/home/20260213785015/en/Philadelphia-Jury-Returns-%24250000-Verdict-Against-JJ-in-Latest-Baby-Powder-Ovarian-Cancer-Trial

21. BriefGlance, Asbestos Litigation Surges as Talc Claims Explode (May 2026) – https://briefglance.com/articles/asbestos-litigation-surges-as-talc-claims-explode-new-report-reveals

22. TorHoerman Law, Johnson & Johnson Talcum Powder Lawsuit Update (May 2026) – https://www.torhoermanlaw.com/johnson-and-johnson-talcum-powder-lawsuit/